Upcoming Webinar: An Overview of Nonclinical Considerations in Translating AAV Gene Therapies to the Clinic

ACT-Signature-Ecard-Banner-BDRP-BTS-STP.png

On Wednesday, February 17 at 11:30 am Eastern (US), BDRP is co-sponsoring a webinar hosted by the American College of Toxicology.

Title: An Overview of Nonclinical Considerations in Translating AAV Gene Therapies to the Clinic

Moderators: Jennifer Daly and Jeffrey Moehlenkamp

Abstract: Adeno-associated viral vectors are currently the most commonly used vectors for gene editing and gene replacement approaches in both CNS and ocular indications. The first part of the presentation will cover case by case considerations for making decisions about nonclinical program design to enable clinical trials of AAV-mediated gene therapies. These will include communication with clinical team members; interactions with regulatory authorities; planning for formulation and delivery of test articles; planning for analytical methods to support toxicology studies; decisions about model selection and justification; dose selection; and study design.

In the second part of the presentation, general regulatory expectations for nonclinical testing of a CRISPR-based gene editing therapeutic will be discussed, including expectations for evaluation of genotoxicity including off-target editing, characterization of gross chromosomal changes, and evaluation of tumorigenicity.

This webinar open to anyone interested. BDRP members will have access to a recording after the live event.

There is no fee but advance registration is required. Register HERE.

Recent Stories
Friends of NIEHS Update from NIEHS and NIH

Recording and Materials from Virtual Hill Briefing on COVID-19 and the Imperative to Include Pregnant and Lactating People in Clinical Trials

FASEB Cosponsors Data Sharing Seminar Series for Societies - Monthly Webinars Starting March 5